Retinoids, retinoic acid receptors, and breast cancer

Jisun Paik1, William S Blaner, Karen M Sommer

  • 1Department of Medicine, Institute of Human Nutrition, Columbia University, New York, New York, USA.

Insights

Retinoids show promise in treating breast cancer by promoting cell differentiation. Further research is needed to clarify their efficacy, side effects, and optimal patient selection for retinoid therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Retinoids are compounds with proven differentiation capabilities.
  • They are investigated for breast cancer prevention and treatment.
  • Controversy exists regarding their efficacy, toxicity, and patient suitability.

Purpose of the Study:

  • To review evidence on retinoid efficacy in human and animal breast cancer models.
  • To explore potential mechanisms of retinoid action in breast cancer.
  • To focus on retinoic acid receptors and metabolic pathways in gene activation.

Main Methods:

  • Review of existing scientific literature on retinoids and breast cancer.
  • Analysis of preclinical (animal models) and clinical (human) data.
  • Examination of molecular mechanisms involving retinoic acid receptors.

Main Results:

  • Evidence suggests retinoids can act as differentiation agents in various neoplasias.
  • Retinoids offer potential therapeutic strategies for breast cancer.
  • Mechanisms involve retinoic acid receptors and metabolic pathways for gene regulation.

Conclusions:

  • Retinoids present a unique therapeutic avenue for breast cancer.
  • Further investigation is required to address efficacy and toxicity concerns.
  • Understanding patient-specific benefits and optimal use is crucial.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...